David H. Abramson
YOU?
Author Swipe
View article: Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy
Refractory Tumorous and Neurodegenerative Histiocytosis Treated With Intra-Arterial Chemotherapy Open
This study provides Class IV evidence that in patients with tumorous or neurodegenerative histiocytosis, selective angiographic catheterization and intra-arterial infusion of melphalan result in radiologic and functional improvement.
View article: In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration
In Vitro Stability and Preclinical Safety Evaluation of High-Dose Intravitreal Topotecan in Rabbits: Impact of Dose and Concentration Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Blood-Based Cell-Free DNA in Ophthalmic Oncology
Blood-Based Cell-Free DNA in Ophthalmic Oncology Open
cfDNA science bridges the gap between basic research and clinical care. Within the field of ophthalmic oncology, cfDNA may be useful as a diagnostic/prognostic tool, for surveillance of metastatic or minimally residual disease, to identify…
View article: High-Dose Topotecan for Recurrent Retinal and Subretinal Retinoblastoma
High-Dose Topotecan for Recurrent Retinal and Subretinal Retinoblastoma Open
Background/Objectives: To report on the efficacy and toxicity of high-dose intravitreal topotecan (90–180 µG) as treatment for recurrent retinal and subretinal retinoblastoma. Methods: We conducted a retrospective review of children with r…
View article: Intraocular Pressure Changes following Intravitreal Topotecan 90 μg/0.18 cc for the Treatment of Retinoblastoma
Intraocular Pressure Changes following Intravitreal Topotecan 90 μg/0.18 cc for the Treatment of Retinoblastoma Open
Introduction: The aim of this study was to investigate the impact of injecting Topotecan 90 μg/0.18 cc on intraocular pressure (IOP) in children with retinoblastoma. Methods: This was a retrospective study of 78 eye encounters of 37 patien…
View article: Detection and Characterization of <i>RB1</i> Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test
Detection and Characterization of <i>RB1</i> Mosaicism in Patients With Retinoblastoma Receiving cfDNA Test Open
Importance Plasma cell-free DNA (cfDNA) testing is increasingly used for disease diagnosis and monitoring in retinoblastoma, with RB1 allele fraction in cfDNA actively corresponding to disease status and treatment response. However, while …
View article: Machine learning demonstrates clinical utility in distinguishing retinoblastoma from pseudo retinoblastoma with RetCam images
Machine learning demonstrates clinical utility in distinguishing retinoblastoma from pseudo retinoblastoma with RetCam images Open
Our machine learning algorithm successfully distinguished retinoblastoma from retinoblastoma with high specificity and sensitivity and if implemented worldwide will prevent hundreds of eyes from incorrectly being surgically removed yearly.
View article: Subfoveal Choroidal Thickness in Patients with Histiocytosis and Multimodal Imaging Features of Choroidal Infiltrates
Subfoveal Choroidal Thickness in Patients with Histiocytosis and Multimodal Imaging Features of Choroidal Infiltrates Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Supplementary Figure S3 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Supplementary Figure S3 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Supplementary Figure S3. Outcome of germline vs sporadic uterine leiomyosarcoma (ULMS) patients.
View article: Supplementary Table S2 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Supplementary Table S2 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Supplementary Table S2. Representativeness of Study Participants.
View article: Supplementary Table S1 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Supplementary Table S1 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Supplementary Table S1. List of LMS patients with germline variants in this study.
View article: Data from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Data from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Purpose:Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous, occurring mostly in sporadic but also syndromic settings. The role of pathogenic germline variants (PGV) as LMS drivers and their impact on outcomes remains uncert…
View article: Supplementary Figure S2 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Supplementary Figure S2 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Supplementary Figure S2. Outcome of germline vs sporadic soft tissue leiomyosarcoma (STLMS) patients.
View article: Supplementary Figure S1 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
Supplementary Figure S1 from The Impact of Li‐Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Supplementary Figure S1. Tumor variant allelic frequency (VAF) vs matched normal VAF in germline pathogenic variants (PGV).
View article: The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations
The Impact of Li-Fraumeni and Germline Retinoblastoma Mutations on Leiomyosarcoma Initiation, Outcomes, and Genetic Testing Recommendations Open
Purpose: Leiomyosarcomas (LMS) are clinically and molecularly heterogeneous, occurring mostly in sporadic but also syndromic settings. The role of pathogenic germline variants (PGV) as LMS drivers and their impact on outcomes remains uncer…
View article: Plasma-Derived Cell-Free DNA for the Diagnosis of Ocular-Involving Histiocytosis
Plasma-Derived Cell-Free DNA for the Diagnosis of Ocular-Involving Histiocytosis Open
Proprietary or commercial disclosure may be found in the Footnotes and Disclosures at the end of this article.
View article: Circulating Tumor DNA Posttreatment Measurements and Clinical Correlates in Retinoblastoma
Circulating Tumor DNA Posttreatment Measurements and Clinical Correlates in Retinoblastoma Open
Importance Plasma measurements of RB1 circulating tumor DNA (ctDNA) after completion of treatment may be associated with the development of metastases in patients with retinoblastoma. Objective To determine if the absence of previously det…
View article: Non-RB1 germline cancer predisposing variants found in retinoblastoma patients
Non-RB1 germline cancer predisposing variants found in retinoblastoma patients Open
In this small cohort of patients with retinoblastoma, non-RB1 variants did not appear to augment tumorigenesis or disease progression. Larger studies are required to determine associations between specific variants and development of SMN.